Stati Uniti - inglese - NLM (National Library of Medicine)

ropack inc. - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - ferric cation 272 mg in 272 mg - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data with triferic use in pregnant women to inform a drug-associated risk. no teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (mrhd) of 27.2 mg per dialysis [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, the maternally toxic ferric pyrophosphate citra

Stati Uniti - inglese - NLM (National Library of Medicine)

rockwell medical, inc - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - ferric cation 5.44 mg in 1 ml - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data with triferic use in pregnant women to inform a drug-associated risk. no teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (mrhd) of 27.2 mg per dialysis [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, the maternally toxic ferric py

Stati Uniti - inglese - NLM (National Library of Medicine)

nartex laboratorios homeopati cos, s.a. de c.v. - ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), avena sativa pollen (unii: a7iky24tr7) (avena sativa pollen - unii:a7iky24tr7), cinchona officinalis whole (unii: 3sxm338giq) (cinchona officinalis whole - unii:3sxm338giq) - ferrosoferric phosphate 8 [hp_x] in 240 g - uses:  relieves symptoms such as: - fatigue - physical weakness - loss of strength as per homeopathic materia medica homeopathic medicine nartex labs revitalix alfalfa (medicago sativa l) cinchona (cinchona officinalis l) ferrosoferric phosphate mexican tradition net 8.12 fl oz (240 ml) relieves symptoms such as fatigue physical weakness and loss of strength

Stati Uniti - inglese - NLM (National Library of Medicine)

coopersurgical, inc. - ferric subsulfate (unii: 3qj8ws6v8h) (ferric cation - unii:91o4lml611) - astringyn® is a styptic agent used for achieving local hemostasis. in punch biopsies of the full dermis, the time to achieve hemostasis is typically less than 20 seconds.1 one method for applying ferric subsulfate solution for dermal use consists of the physician placing fingers at the opposite edges of the wound and stretching the skin. the wound is then wiped with gauze, the ferric subsulfate solution applied, and the tension maintained for approximately 15 seconds.2  

Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - ferric carboxymaltose -

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - iron carboxymaltose 179 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - iron, parenteral preparations

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - iron carboxymaltose 179 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - iron, parenteral preparations

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - iron carboxymaltose 179 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - iron, parenteral preparations

Stati Uniti - inglese - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. sodium ferric gluconate complex in sucrose injection is contraindicated in patients with known hypersensitivity to sodium ferric gluconate or any of its components. reactions have included anaphylaxis [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [see warnings and precautions (5.1) ], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant women of the potential risk to the fetus. available data from postmarketing reports with sodium ferric gluconate complex in sucrose injection use in pregnancy are insufficient to assess the risk of major birth defects and miscarriage. sodium ferric gluconate comple

Stati Uniti - inglese - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. sodium ferric gluconate complex in sucrose injection is contraindicated in patients with known hypersensitivity to sodium ferric gluconate or any of its components. reactions have included anaphylaxis [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [see warnings and precautions (5.1) ], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant women of the potential risk to the fetus. available data from postmarketing reports with sodium ferric gluconate complex in sucrose injection use in pregnancy are insufficient to assess the risk of major birth defects and miscarriage. sodium ferric gluconate comple